News

Tapering immunosuppressive corticosteroids as much as possible during the first year of treatment for ANCA-associated vasculitis (AAV) reduced long-term complications associated with the disorder, an analysis in Japan finds. Recent developments in AAV treatments have led to faster disease remission and fewer relapses in Asian patients, allowing for…

A higher eosinophil count at diagnosis is linked to more severe disease activity in people with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), the two most common types of ANCA-associated vasculitis (AAV), a study suggests. Counting eosinophils, white blood cells that usually release enzymes and other molecules in…

At ANCA Vasculitis News, we have spent the last year bringing you coverage of the latest developments in research and treatment for ANCA-associated vasculitis (AAV). Here, we’ve compiled a list of the top 10 most-read articles of 2023, with a brief description of each. We look forward to…

People newly diagnosed with microscopic polyangiitis (MPA) — a type of ANCA-associated vasculitis (AAV) — already considered to be more severe by two established measures are a higher risk of death, a study of patient registry data from Japan reports. The severity of MPA, one of the three main…

Self-reactive anti-neutrophil cytoplasmic antibodies, or ANCAs, may play a unique role in driving blood vessel inflammation in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis (AAV). That’s according to a small study, which found that disease relapses outside the respiratory system occurred only in EGPA…

Evotec has formed a partnership with Charité – Universitätsmedizin Berlin in Germany to build a database of all sorts of molecular information from people with ANCA-associated vasculitis (AAV). Molecular profiles, a kind of fingerprint of AAV, may help scientists better understand the autoimmune disease and pave the way…

Factor XII (FXII), a protein involved in blood clotting, is found at significantly higher levels in the blood of people with active ANCA-associated vasculitis (AAV) relative to those in clinical remission, or whose symptoms have eased or disappeared. That’s according to a study in China that also found that…

ANCA-associated vasculitis (AAV) with kidney involvement is the most common cause of kidney disease among elderly people, but most older patients appear to benefit from appropriate therapy as well as younger AAV patients with kidney damage. That’s according to a study in Germany that found no significant differences in…

A first patient has been dosed in a Phase 2 clinical trial testing lixudebart, Alentis Therapeutics‘ investigational antibody therapy, in ANCA-associated vasculitis (AAV) patients with rapidly progressing glomerulonephritis (RPGN), a serious kidney disease. The study, RENAL-F02 (NCT06047171), currently is recruiting up to 60 adults with AAV…

ANCA-associated vasculitis (AAV) patients who are older and taking pulses of methylprednisolone as an induction therapy are more likely to have a greater drop in protective IgG antibody levels during maintenance therapy with rituximab, raising a significant risk of severe infections, a study from France reports. A lower…